Panacea Biotec Ltd

Panacea Biotec Ltd is rated 'Strong Sell' by MarketsMOJO, with this rating last updated on 31 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Panacea Biotec Ltd recorded a robust intraday performance on 10 Mar 2026, surging to a day’s high of Rs 359.8, marking a 7.47% gain. The stock outpaced the broader market and its sector, reflecting notable trading momentum amid a mixed market backdrop.

Panacea Biotec Ltd commenced trading today with a significant gap up, opening 7.72% higher than its previous close, signalling a robust start amid positive market sentiment. The stock outperformed its sector and broader indices, continuing a short-term upward trajectory following two consecutive days of gains.

Panacea Biotec Ltd’s shares declined to a fresh 52-week low of Rs.306 on 9 March 2026, marking a significant milestone in the stock’s ongoing downward trajectory. This new low reflects persistent pressures on the company’s financial performance and market valuation, as it continues to underperform relative to broader indices and sector peers.

Panacea Biotec Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 31 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 March 2026, providing investors with the latest insights into the company’s performance and outlook.

Panacea Biotec Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 31 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 February 2026, providing investors with the latest insights into the company’s performance and outlook.

Panacea Biotec Ltd has experienced a notable shift in its technical momentum, with key indicators signalling a bearish trend. Despite a strong long-term performance relative to the Sensex, recent weekly and monthly technical parameters suggest increasing downside pressure on the stock, prompting a downgrade to a Strong Sell rating.

Panacea Biotec Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 31 October 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 13 February 2026, providing investors with an up-to-date view of the stock’s fundamentals, valuation, financial trends, and technical outlook.

Panacea Biotec Ltd has experienced a nuanced shift in its technical momentum, moving from a bearish stance to a mildly bearish outlook, reflecting a complex interplay of technical indicators. Despite a modest daily price increase to ₹356.50, the stock faces headwinds from key moving averages and Bollinger Bands, while some weekly indicators hint at emerging bullish tendencies. This article analyses the latest technical signals and market context to provide a comprehensive view of Panacea Biotec’s current positioning within the Pharmaceuticals & Biotechnology sector.

Panacea Biotec Ltd’s latest quarterly results for December 2025 reveal a stabilisation in financial performance after a period of decline, with key profitability metrics reaching new highs despite flat revenue growth. The company’s operating profit margin expanded to 7.11%, while net profit after tax hit its highest quarterly level in recent times. However, concerns remain over cash reserves and reliance on non-operating income, prompting a cautious outlook from analysts.

Panacea Biotec Ltd., the research-based pharmaceuticals and biotechnology company, posted a consolidated net profit of ₹3.98 crores in Q3 FY26 (December 2025 quarter), marking an 11.95% decline year-on-year from ₹4.52 crores in the corresponding quarter last year. The stock, currently trading at ₹357.25 with a market capitalisation of ₹2,188.18 crores, has underperformed the broader market significantly, delivering a marginal 0.45% return over the past year compared to the Sensex's 10.15% gain.

Panacea Biotec Ltd has experienced a notable shift in price momentum, with technical indicators signalling a bearish trend. The company’s Mojo Grade was downgraded from Sell to Strong Sell on 31 Oct 2025, reflecting deteriorating market sentiment amid a 5.4% decline in the latest trading session. This article analyses the recent technical parameter changes, key indicator signals, and the implications for investors in the Pharmaceuticals & Biotechnology sector.

Panacea Biotec Ltd has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a modest daily gain of 2.06%, the stock’s technical indicators reveal a transition from a predominantly bearish stance to a mildly bearish outlook, underscoring the need for cautious investor appraisal amid mixed market conditions.

Panacea Biotec Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with recent indicators signalling a bearish outlook. The company’s stock price has declined to ₹361.55, down 2.19% from the previous close of ₹369.65, reflecting growing investor caution amid mixed technical signals and a downgrade in its Mojo Grade to Strong Sell.

Panacea Biotec Ltd has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a recent upgrade in its Mojo Grade to Strong Sell from Sell, the stock’s price action and technical indicators reveal a cautiously evolving landscape for investors in the Pharmaceuticals & Biotechnology sector.